other material
confidence high
sentiment positive
materiality 0.65
Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; durable remissions without rebound
Corvus Pharmaceuticals, Inc.
- 72-patient Phase 1 trial met safety and efficacy endpoints; no severe adverse events.
- Cohort 4 (200 mg BID for 56 days): 75% achieved EASI 75, 25% achieved EASI 90, 33% IGA 0/1.
- Biomarker data confirms ITK inhibition reduces Th2/Th17 cytokines and increases persistent Tregs.
- Drug-free remission maintained in post-treatment follow-up (up to 90 days) with no disease rebound.
- SIERRA1 Phase 2 trial for moderate-to-severe atopic dermatitis now enrolling ~200 patients.